Crossmark

Benefits of neoadjuvant chemotherapy: is the prognosis of ypN0 patients after neoadjuvant chemotherapy comparable to that of pN0 patients undergoing surgery alone?

Crossref DOI link: https://doi.org/10.1007/s10388-025-01132-9

Published Online: 2025-05-20

Published Print: 2025-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shiraishi, Osamu https://orcid.org/0000-0002-4740-5422
Tanaka, Koji

Makino, Tomoki

Sugase, Takahito

Kanemura, Takashi

Takeno, Atsushi

Sugimura, Keijiro

Motoori, Masaaki

Kimura, Yutaka

Hirao, Motohiro

Fujitani, Kazumasa

Miyata, Hiroshi

Yano, Masahiko

Yamasaki, Makoto

Doki, Yuichiro

Yasuda, Takushi
License Information

Text and Data Mining valid from 2025-05-20

Version of Record valid from 2025-05-20
More Information

Article History

Received: 4 April 2025

Accepted: 12 May 2025

First Online: 20 May 2025

Declarations

:

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.

: The authors have declared no conflicts of interest.

Document is current

Any future updates will be listed below